BSE filing, NSE: HESTERBIO. Summary written from the filing by ALFA Finder's alert engine.
Hester Biosciences Ltd: key numbers
- Share price
- ₹2,232.00
- Market cap
- ₹1,899 Cr
- Revenue (annual)
- ₹332.6 Cr
- Net profit (annual)
- ₹55.64 Cr
- P/E (TTM)
- 13.9×Sector 46.5×
- Promoter holding
- 44.28%-9.45% QoQ
- FII holding
- 0.30%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Hester Biosciences Ltd
All →Hester Biosciences Management Change
Hester Biosciences disclosed Independent Director Mr. Ameetkumar Desai ceased his role on 27 October 2026 upon completing his first tenure. He opted not to seek re-appointment.
Hester Biosciences Other Announcement
Hester Biosciences reported shareholding data for the quarter ending September 2026. Two promoters were reclassified as public shareholders, reducing the promoter holding.
Hester Biosciences Capacity Expansion: ₹1.05 Cr Investment
Hester Biosciences' board approved a ₹1.05 Cr stake in SLYCE AGRI WORLD LLP for captive solar power generation. The PPA secures captive electricity supply to the company.
- Value
- ₹1.05 Cr
- Execution
- six months
Hester Biosciences Promoter Reclassification
Hester Biosciences Limited received shareholder approval to reclassify Mr. Ravin Gandhi and Ms. Bela Gandhi from the 'Promoter' category to the 'Public' category.
Hester Biosciences Annual General Meeting
Hester Biosciences Limited shareholders approved the reclassification of Mr. Ravin Gandhi and Ms. Bela Gandhi from 'Promoter' to 'Public' category via postal ballot.
Hester Biosciences Credit Rating
Hester Biosciences Ltd received an upgrade in its long-term and short-term bank facility credit ratings from CARE Ratings.
Other board meeting date announcements
All →Jetking Infotrain Board Meeting Date
Jetking Infotrain has scheduled a board meeting on November 4, 2026 to consider unaudited quarterly and half-year results. The trading window remains closed until 48 hours after the results announcement.
Metropolis Healthcare Board Meeting Date
Metropolis Healthcare intimated a board meeting on November 3, 2026 to consider Q2 and half-year unaudited results and possible interim dividend. Trading window is closed October 1 to November 5, 2026.
Aelea Commodities Board Meeting Date
Aelea Commodities has scheduled a board meeting for 2 November 2026 to consider half-year results and other items. The agenda includes an additional independent director, a director resignation, and business expansion and capex.
R Systems International Board Meeting Date
R Systems International will hold a board meeting on 3 November 2026 to consider quarterly and nine-month results to September 2026. The trading window remains closed until 48 hours after the results are declared.
Onida Electronics Board Meeting Date
Onida Electronics schedules a 3 November 2026 board meeting for Q2 and half-year results and ESOP share allotment. Trading window stays closed until 48 hours post-results.
Platinum Industries Board Meeting Date
Platinum Industries Ltd intimated a board meeting on November 4, 2026 to approve unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. Trading window closed from October 1, 2026.